Literature DB >> 1386050

Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse.

Y Calmus1, B Weill, Y Ozier, C Chéreau, D Houssin, R Poupon.   

Abstract

Cell-mediated immunity is impaired during cholestasis, and there is evidence that bile acids play a role in this immune defect. Ursodeoxycholic acid (UDCA), which corrects the immunological abnormalities observed in primary biliary cirrhosis, could counter the detrimental effects of the endogenous bile acids. Accordingly, we assessed the respective effects of cholestasis, chenodeoxycholic acid (CDCA), and UDCA, using mixed lymphocyte culture as a model of allogeneic immune response. CDCA induced a dose-dependent inhibition of the proliferative response (0-150 mumol/L). Mononuclear cells obtained from bile duct-ligated mice had a normal immunostimulatory effect, whereas responder cells obtained from such animals showed a profoundly impaired proliferative response, suggesting that responder T cels are the main target of the cholestasis-induced immune defect. Supplementation of cultures with exogenous interleukins partially compensated for the inhibitory effect of 25 mumol/L CDCA, but not for that of 50 mumol/L CDCA, suggesting that impaired secretion of interleukins is not the only factor involved in the effect of bile acids. In contrast to CDCA, UDCA had no inhibitory effect on the allogenic immune response at concentrations of up to 50 mumol/L.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386050     DOI: 10.1016/0016-5085(92)90855-s

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

1.  Beneficial effects of glycocholic acid (GCA) on gut mucosal damage in bile duct ligated rats.

Authors:  B K Oktar; M A Gülpinar; F Ercan; A Cingi; I Alican; B C Yegen
Journal:  Inflammation       Date:  2001-10       Impact factor: 4.092

2.  The ursodeoxycholic acid story in primary biliary cirrhosis.

Authors:  A G Lim; R P Jazrawi; T C Northfield
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

3.  Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant.

Authors:  Jennifer E Guy; Peiqing Qian; Jeffrey A Lowell; Marion G Peters
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

4.  Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis.

Authors:  K E Kisand; A L Karvonen; M Vuoristo; M Färkkilä; J Lehtola; J Inkovaara; K V Kisand; T Miettinen; K Krohn; R Uibo
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

5.  Effects of chenodeoxycholic and ursodeoxycholic acids on interferon-gamma production by peripheral blood mononuclear cells from patients with primary biliary cirrhosis.

Authors:  R Saeki; H Ogino; S Kaneko; M Unoura; K Kobayashi
Journal:  J Gastroenterol       Date:  1995-12       Impact factor: 7.527

Review 6.  Recurrent primary biliary cirrhosis after liver transplantation--the disease and its management.

Authors:  Ian Schreibman; Arie Regev
Journal:  MedGenMed       Date:  2006-05-03

Review 7.  Overlap syndromes of autoimmune hepatitis: what is known so far.

Authors:  Marilena Durazzo; Alberto Premoli; Sharmila Fagoonee; Rinaldo Pellicano
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

8.  Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A.

Authors:  J C Duclos-Vallée; A Hadengue; N Ganne-Carrié; E Robin; C Degott; S Erlinger
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

9.  Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis.

Authors:  Y Nishigaki; H Ohnishi; H Moriwaki; Y Muto
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.